CPIX · Cumberland Pharmaceuticals Inc
$7.65
+0.15 (+2.00%)
At close · Aug 21
Market Cap
$114.62M
Shares
14.98M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$44.52M
+17.6%
FY2025
Net Income
-$2.84M
+56.2%
FY2025
Gross Margin
85.02%
+2.4pp
FY2025
Operating Margin
-6.27%
+10.7pp
FY2025
Diluted EPS
-$0.19
+58.7%
FY2025
Operating Cash Flow
$4.93M
+905.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $31.27M | $44.52M | $37.87M | $39.55M | $42.01M | $35.99M | $37.44M | $34.39M | $29.34M | $41.15M | $33.03M | $900K | $600K | $800K | $700K | $51.14M | $45.88M | $43.54M | |
| $7.18M | $6.67M | $6.59M | $6.07M | $9.12M | $8.81M | $8.65M | $7.42M | $6.02M | $7.37M | $5.96M | $4.97M | $5.05M | $5.44M | $5.05M | $5.36M | $3.59M | $4.14M | |
| $24.31M | $37.85M | $31.28M | $33.49M | $32.89M | $27.17M | $28.79M | $26.97M | $23.33M | $33.78M | $27.07M | -$4.07M | -$4.45M | -$4.64M | -$4.35M | $45.78M | $42.29M | $39.4M | |
| — | 85.02% | 82.61% | 84.66% | 78.29% | 75.51% | 76.89% | 78.42% | 79.5% | 82.09% | 81.96% | -452.02% | -742.19% | -579.93% | -620.88% | 89.51% | 92.18% | 90.5% | |
| $5.66M | $5.57M | $4.82M | $5.83M | $6.69M | $5.68M | $5.77M | $6.87M | $7.58M | $4.28M | $3.19M | $3.85M | $3.39M | $5.62M | $5.1M | $5.03M | $4.33M | $4.99M | |
| $19.93M | $19.1M | $17.02M | $18.45M | $16.66M | $15.02M | $14.77M | $15.28M | $14M | $21.49M | $14.55M | $13.99M | $14.9M | $14.39M | $20.33M | $20.94M | $22.67M | $20.19M | |
| $11.93M | $11.95M | $11.13M | $10.65M | $10.18M | $9.78M | $10.2M | $9.97M | $10.15M | $9.65M | $8.56M | $7.61M | $8.4M | $9.49M | $9.06M | $9.31M | $8.1M | $7.64M | |
| $4.28M | $4.03M | $4.75M | $8.1M | $5.07M | $4.37M | $4.43M | $4.13M | $2.77M | $2.44M | $2.19M | $1.99M | $1.6M | $896.16K | $506.33K | $655.3K | $686.91K | $686.9K | |
| — | $4.15M | $4.9M | $4.94M | $5.33M | $4.61M | $4.75M | $4.4M | $2.98M | $2.65M | $2.4M | $2.25M | $1.99M | $1.3M | $901.65K | $1.04M | $978.4K | $816.5K | |
| $48.98M | $47.31M | $44.3M | $49.11M | $47.72M | $43.66M | $43.82M | $43.68M | $40.52M | $45.23M | $34.46M | $32.41M | $33.34M | $35.83M | $40.03M | $41.29M | $39.37M | $37.76M | |
| -$9.63M | -$2.79M | -$6.43M | -$9.55M | -$5.7M | -$7.68M | -$6.38M | -$9.29M | -$11.17M | -$4.08M | -$1.43M | $1.11M | $3.56M | -$3.8M | $8.82M | $9.85M | $6.5M | $5.78M | |
| — | -6.27% | -16.99% | -24.16% | -13.58% | -21.34% | -17.04% | -27.01% | -38.07% | -9.92% | -4.34% | 123.51% | 593.14% | -475.17% | 1259.73% | 19.26% | 14.17% | 13.27% | |
| — | $1.35M | -$1.53M | -$4.62M | -$376.82K | -$3.07M | -$1.63M | -$4.88M | -$8.19M | -$1.43M | $963.78K | $3.36M | $5.55M | -$2.5M | $9.72M | $10.89M | $7.48M | $6.59M | |
| $418.28K | $495.99K | $605.51K | $667.86K | $586K | $98.03K | $263.63K | $246.19K | $195.85K | $92.9K | $106.39K | $73.86K | $67.07K | $103.42K | $71.99K | $353.5K | $1.42M | $772.93K | |
| $362.47K | $476.75K | $334.44K | $286.85K | $98.41K | $26.08K | $75.35K | $243.36K | $564.48K | $299.33K | $204.66K | $209.18K | $251.45K | $230.29K | $304.87K | $210.73K | $200.21K | $79.36K | |
| — | -$13.22K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$13.22K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$7.31M | -$2.81M | -$6.47M | -$6.28M | -$5.58M | -$5.56M | -$6.57M | -$9.29M | -$10.8M | -$3.87M | -$1.33M | $1.25M | $3.74M | -$3.67M | $9.05M | $9.71M | $5.28M | $5.08M | |
| $36.66K | $40.26K | -$22.67K | $45.77K | $68.85K | $34.89K | $55.9K | -$79.32K | $16.64K | $4.17M | -$330.92K | $575.83K | $1.38M | -$1.52M | $3.24M | $4.08M | $2.85M | $2.02M | |
| -$10.92M | -$2.84M | -$6.48M | -$6.28M | -$5.57M | -$3.51M | -$3.34M | -$3.54M | -$6.96M | -$7.98M | -$944.68K | $731.35K | $2.42M | -$2.1M | $5.84M | $5.66M | $2.46M | $3.09M | |
| — | -6.37% | -17.11% | -15.88% | -13.26% | -9.75% | -8.92% | -10.29% | -23.73% | -19.39% | -2.86% | 81.26% | 403.95% | -263.08% | 834.64% | 11.06% | 5.36% | 7.1% | |
| -$20.7K | -$28.58K | $36.06K | -$51.45K | -$79.8K | -$95.21K | -$79.5K | -$8752 | -$75.7K | -$71.18K | -$59.26K | -$60.24K | -$61.26K | -$46.8K | -$36.29K | -$31.34K | -$29.67K | -$32.54K | |
| -$4.57M | — | — | — | — | — | — | -$3.55M | -$7.04M | -$8.05M | -$1M | $671.11K | $2.36M | -$2.15M | $5.81M | $5.63M | $2.43M | — | |
| USD/shares | — | -$0.19 | -$0.46 | -$0.44 | -$0.38 | -$0.24 | -$0.22 | -$0.23 | -$0.45 | -$0.50 | -$0.06 | $0.04 | $0.14 | -$0.11 | $0.30 | $0.28 | $0.12 | $0.22 |
| USD/shares | — | -$0.19 | -$0.46 | -$0.44 | -$0.38 | -$0.24 | -$0.22 | -$0.23 | -$0.45 | -$0.50 | -$0.06 | $0.04 | $0.14 | -$0.11 | $0.30 | $0.28 | $0.12 | $0.17 |
| shares | — | 14.85M | 14.06M | 14.3M | 14.56M | 14.9M | 15.16M | 15.4M | 15.61M | 15.91M | 16.24M | 16.72M | 17.62M | 18.33M | 19.56M | 20.34M | 20.33M | 14.2M |
| shares | — | 14.85M | 14.06M | 14.3M | 14.56M | 14.9M | 15.16M | 15.4M | 15.61M | 15.91M | 16.24M | 17.09M | 17.9M | 18.33M | 19.79M | 20.57M | 21.06M | 18.23M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2025: $77.43M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.47×
EV/EBIT
—
Peer median 8.66×
P/E (TTM)
—
Peer median 6.00×
Peer medians compare against the 50 similar-size Drug Manufacturers - Specialty & Generic companies (of 104 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Non Us | $4,900,000 | $2,700,000 | $1,100,000 | $1,500,000 | $2,200,000 | $2,400,000 | $1,500,000 | $2,100,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $40,396,278 | $36,537,704 | $37,513,492 | $40,681,182 | $35,045,259 | $35,840,673 | $32,407,845 | $28,803,961 |
| Product Sancuso | $11,907,141 | $9,005,129 | $8,096,788 | $13,205,603 | — | — | — | — |
| Product Kristalose | $10,542,793 | $15,315,259 | $15,981,850 | $15,205,155 | — | — | — | — |
| Product Vibativ | $9,484,874 | $7,160,125 | $8,812,692 | $7,487,462 | $11,704,062 | $10,870,990 | $8,691,550 | $5,075,057 |
| Product Caldolor | $4,659,457 | $4,959,385 | $4,333,923 | $4,827,200 | — | — | — | — |
| Product Other | $4,125,153 | $1,330,241 | — | — | — | — | — | — |
| Manufactured Product Other | $4,125,153 | $1,330,241 | $2,039,015 | $1,329,767 | $939,784 | $1,600,461 | $1,980,450 | $540,933 |
| Product Talicia | $3,311,235 | $0 | — | — | — | — | — | — |
| Product Acetadote | $508,169 | $185,182 | $458,759 | $501,040 | — | — | — | — |
| Product RediTrex | $11,391 | $90,237 | -$341,886 | -$126,726 | — | — | — | — |
| Product Omeclamox Pak | -$10,436 | -$3,075 | $20,030 | $29,145 | — | — | — | — |
| Product Vaprisol | -$18,346 | -$174,538 | $151,336 | -$447,697 | — | — | — | — |
| Acetadote | — | — | — | $501,040 | $850,993 | $1,874,206 | $3,824,449 | $4,284,111 |
| Caldolor | — | — | — | $4,827,200 | $4,970,301 | $5,336,943 | $5,222,282 | $5,001,997 |
| Kristalose | — | — | — | $15,205,155 | $15,993,658 | $15,567,562 | $12,895,120 | $12,055,625 |
| Omeclamox Pak | — | — | — | — | -$388,657 | $257,088 | $837,829 | $623,297 |
| Product Ethyol | — | — | — | — | — | — | $12,774,831 | $10,545,906 |
| Product Totect | — | — | — | — | — | — | $369,912 | $850,965 |
| RediTrex | — | — | — | -$126,726 | $55,321 | $856,657 | — | — |
| Sancuso | — | — | — | $13,205,603 | $0 | — | — | — |
| Vaprisol | — | — | — | -$447,697 | $1,859,581 | $1,077,227 | $936,615 | $1,763,874 |
Key facts
CIK
1087294
CUSIP
230770109
13F (30d)
32 filings
32 filers
Visit website
Investor relations